

### **Listing of Claims:**

Claims 1-36 (canceled)

Claim 37 (new): A sheet of material adapted for implantation between tissues of a human body, the sheet of material including an attached anti-proliferative drug, the anti-proliferative drug being designed to reduce the generation of scar tissue, the anti-proliferative drug being selected from the group consisting of Rapamycin, tacrolimus (FK506), and one of the following analogs of sirolimus: SDZ-RAD, CCI-779, 7-epi-rapamycin, 7-thiomethyl-rapamycin, 7-epi-trimethoxyphenyl-rapamycin, 7-epi-thiomethyl-rapamycin, 7-demethoxy-rapamycin, 32-demethoxy, 2-desmethyl and proline.

Claim 38 (new): The apparatus of claim 37 wherein the sheet of material is biodegradable.

Claim 39 (new): The apparatus of claim 37 wherein the sheet of material is in the form of a mesh.

Claim 40 (new): In combination, including an anti-proliferative drug attached to a bandage for placement over a cut on the skin of a human subject, the anti-proliferative drug being selected from the group consisting of tacrolimus (FK506), Rapamycin and one of the following analogs of sirolimus: SDZ-RAD, CCI-779, 7-epi-rapamycin, 7-thiomethyl-rapamycin, 7-epi-trimethoxyphenyl-rapamycin, 7-epi-thiomethyl-rapamycin, 7-demethoxy-rapamycin, 32-demethoxy, 2-desmethyl and proline.

Claim 41 (new): In combination, including an anti-proliferative drug attached to a surgical suture, the suture being adapted to connect human tissue that is separated by a surgical procedure on a human subject, the anti-proliferative drug being selected from the group consisting of tacrolimus (FK506), Rapamycin and one of the following analogs of sirolimus: SDZ-RAD, CCI-779, 7-epi-rapamycin, 7-thiomethyl-rapamycin, 7-epi-trimethoxyphenyl-rapamycin, 7-epi-thiomethyl-rapamycin, 7-demethoxy-rapamycin, 32-demethoxy, 2-desmethyl and proline.

Claim 42 (new): In combination, including an anti-proliferative drug attached to a mesh having a generally cylindrical shape for introduction into a generally cylindrical cavity of the human body to decrease scar tissue formation in that generally cylindrical cavity after a surgical procedure on that generally cylindrical cavity, the anti-proliferative drug being selected from the group consisting of tacrolimus (FK506), Rapamycin and one of the following analogs of sirolimus: SDZ-RAD, CCI-779, 7-epi-rapamycin, 7-thiomethyl-rapamycin, 7-epi-trimethoxyphenyl-rapamycin, 7-epi-thiomethyl-rapamycin, 7-demethoxy-rapamycin, 32-demethoxy, 2-desmethyl and proline.

Claim 43 (new): The combination of claim 42 wherein the generally cylindrical cavity is a human nostril.

Claim 44 (new): A device to reduce scar tissue formation within the eye of a human subject after a retinal attachment procedure, including a buckle designed to be placed onto the eye, the buckle including an attached anti-proliferative, the anti-proliferative drug being selected from the group consisting of tacrolimus (FK506), Rapamycin and one of the following analogs of sirolimus: SDZ-RAD, CCI-779, 7-epi-rapamycin, 7-thiomethyl-rapamycin, 7-epi-trimethoxyphenyl-rapamycin, 7-epi-thiomethyl-rapamycin, 7-demethoxy-rapamycin, 32-demethoxy, 2-desmethyl and proline.

Claim 45 (new): An implantable device adapted for surgical implantation within a space within a human body at a location that is external to any vessel of that human body, at least part of the device including an attached anti-proliferative drug, the action of the anti-proliferative drug being a reduction in the generation of scar tissue, the anti-proliferative drug being selected from the group consisting of Rapamycin, tacrolimus (FK506), and one of the following analogs of sirolimus: SDZ-RAD, CCI-779, 7-epi-rapamycin, 7-thiomethyl-rapamycin, 7-epi-trimethoxyphenyl-rapamycin, 7-epi-thiomethyl-rapamycin, 7-demethoxy-rapamycin, 32-demethoxy, 2-desmethyl and proline.

Claim 46 (new): The device of claim 45 wherein the device is in the form of a prosthetic breast implant.

Claim 47 (new): The device of claim 45 wherein the device is in the form of an arterio-venous fistula shunt.

Claim 48 (new): A method for improving the outcome of a surgical procedure, the method being the release into a human subject on whom the surgical procedure has been performed of an anti-proliferative agent in combination with at least one other drug selected from the group consisting of antiseptic agents, anti-biotic agents and analgesic agents, and the anti-proliferative agent being selected from the group consisting of Rapamycin, tacrolimus (FK506), and one of the following analogs of sirolimus: SDZ-RAD, CCI-779, 7-epi-rapamycin, 7-thiomethyl-rapamycin, 7-epi-trimethoxyphenyl-rapamycin, 7-epi-thiomethyl-rapamycin, 7-demethoxy-rapamycin, 32-demethoxy, 2-desmethyl and proline.

Claim 49 (new): The method of claim 48 wherein the anti-proliferative agent is used in an ointment that is applied to the skin.

Claim 50 (new): The method of claim 48 wherein the anti-proliferative agent is attached to a mesh that is adapted to be placed within the human subject in whom the surgical procedure was performed.

Claim 51 (new): The method of claim 48 wherein the anti-proliferative agent is attached to a breast implant.

Claim 52 (new): The method of claim 48 wherein the anti-proliferative agent is attached to a suture.

Claim 53 (new): The method of claim 48 wherein the anti-proliferative agent is released systemically.

Claim 54 (new): A method for decreasing the formation of scar tissue after a surgical procedure, the method comprising the following steps:

a) attaching an anti-proliferative drug onto a sheet of material designed to be placed onto or into a human subject; the anti-proliferative drug being selected from the group consisting of Rapamycin, tacrolimus (FK506), and one of the following analogs of sirolimus: SDZ-RAD, CCI-779, 7-epi-rapamycin, 7-thiomethyl-rapamycin, 7-epi-trimethoxyphenyl-rapamycin, 7-epi-thiomethyl-rapamycin, 7-demethoxy-rapamycin, 32-demethoxy, 2-desmethyl and proline; and

b) placing the mesh with the attached anti-proliferative drug onto or into a human subject during or after completing a surgical procedure.

Claim 55 (new): The method of claim 54 further including the step of systemic application of at least one anti-proliferative drug at least one day prior to the surgical procedure.

Claim 56 (new): The method of claim 54 further including the step of a continuing systemic application of at least one anti-proliferative drug for at least one day after the surgical procedure.

Claim 57 (new): In combination, an anti-proliferative drug attached to a breast implant, the breast implant being designed to provide breast enlargement for a human female subject, the anti-proliferative drug being selected from the group that includes 'taclolimus (FK506), Rapamycin and the following analogs of sirolimus: SDZ-RAD, CCI-779, 7-epi-rapamycin, 7-thiomethyl-rapamycin, 7-epi-trimethoxyphenyl-rapamycin, 7-epi-thiomethyl-rapamycin, 7-demethoxy-rapamycin, 32-demethoxy, 2-desmethyl and proline.

Claim 58 (new): A sheet of material adapted for implantation between tissues of a human body, at least part of the sheet of material having an anti-proliferative drug attached, the action of the anti-proliferative drug being a reduction in the generation of scar tissue, the anti-proliferative drug being selected from the group that includes Rapamycin, Taxol, Alkeran, Cytoxan, Leukeran, Cis-platinum, BiCNU, Adriamycin, Doxorubicin, Cerubidine, Idamycin, Mithracin, Mutamycin, Fluorouracil, Methotrexate, Thoguanine, Toxotere, Etoposide, Vincristine, Irinotecan, Hycamptin, Matulane, Vumon, Hexalin, Hydroxyurea, Gemzar, Oncovin and Etophophos, taclolimus (FK506), and the following analogs of sirolimus: SDZ-RAD, CCI-779, 7-epi-rapamycin, 7-thiomethyl-rapamycin, 7-epi-trimethoxyphenyl-- rapamycin, 7-epi-thiomethyl-rapamycin, 7-demethoxy-rapamycin, 32-demethoxy, 2-desmethyl and proline.

Claim 59 (new): A device adapted for implantation within a human body, at least part of the device having an anti-proliferative drug attached, the action of the anti-proliferative drug being a reduction in the generation of scar tissue, the anti-proliferative drug being selected from the group that includes Rapamycin, Taxol, Alkeran, Cytoxan, Leukeran, Cis-

platinum, BiCNU, Adriamycin, Doxorubicin, Cerubidine, Idamycin, Mithracin, Mutamycin, Fluorouracil, Methotrexate, Thoguanine, Toxotere, Etoposide, Vincristine, Irinotecan, Hycamptin, Matulane, Vumon, Hexalin, Hydroxyurea, Gemzar, Oncovin and Etophophos, tacrolimus (FK506), and the following analogs of sirolimus: SDZ-RAD, CCI-779, 7-epi-rapamycin, 7-thiomethyl-rapamycin, 7-epi-trimethoxyphenyl-rapamycin, 7-epi-thiomethyl-rapamycin, 7-demethoxy-rapamycin, 32-demethoxy, 2-desmethyl and proline.

Claim 60 (new): A method for decreasing the formation of scar tissue after a surgical procedure, the method comprising the following steps: a) attaching an anti-proliferative drug onto a mesh for placement onto or into a human subject; the antiproliferative drug being selected from the group that includes tacrolimus (FK506), and the following analogs of sirolimus: SDZ-RAD, CCI-779, 7-epi-rapamycin, 7-thiomethyl-rapamycin, 7-epi-trimethoxyphenyl-rapamycin, 7-epi-thiomethyl-rapamycin, 7-demethoxy-rapamycin, 32-demethoxy, 2-desmethyl and proline. b) placing the mesh with attached anti-proliferative drug onto or into a human subject during or after completing a surgical procedure.

Claim 61 (new): A method for decreasing scar tissue formation on a cut in the skin of a human subject, the method comprising the following steps: a) placing an ointment onto the skin at the site of the cut, the ointment including an anti-proliferative agent selected from the group that includes Rapamycin, Taxol, Alkeran, Cytosan, Leukeran, Cis-platinum, BiCNU, Adriamycin, Doxorubicin, Cerubidine, Idamycin, Mithracin, Mutamycin, Fluorouracil, Methotrexate, Thoguanine, Toxotere, Etoposide, Vincristine, Irinotecan, Hycamptin, Matulane, Vumon, Hexalin, Hydroxyurea, Gemzar, Oncovin and Etophophos, tacrolimus (FK506), and the following analogs of sirolimus: SDZ-RAD, CCI-779, 7-epi-rapamycin, 7-thiomethyl-rapamycin, 7-epi-trimethoxyphenyl-rapamycin, 7-epi-thiomethyl-rapamycin, 7-demethoxy-rapamycin, 32-demethoxy, 2-desmethyl and proline; and b) placing a bandage over the ointment, the bandage being attached to the skin in the vicinity of the cut.

Claim 62 (new): The method of claim 61 further including the step of the systemic administration of at least one anti-proliferative agent selected from the group that includes Rapamycin, Taxol, Alkeran, Cytosan, Leukeran, Cis-platinum, BiCNU, Adriamycin, Doxorubicin, Cerubidine, Idamycin, Mithracin, Mutamycin, Fluorouracil, Methotrexate, Thoguanine, Toxotere, Etoposide, Vincristine, Irinotecan, Hycamptin, Matulane, Vumon, Hexalin, Hydroxyurea, Gemzar, Oncovin and Etophophos, tacrolimus (FK506), and the

following analogs of sirolimus: SDZ-RAD, CCI-779, 7-epi-rapamycin, 7-thiomethyl-rapamycin, 7-epi-trimethoxyphenyl-rapamycin, 7-epi-thiomethyl-rapamycin, 7-demethoxy-rapamycin, 32-demethoxy, 2-desmethyl and proline.